146 related articles for article (PubMed ID: 22398048)
1. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels.
Tavano F; di Mola FF; Latiano A; Palmieri O; Bossa F; Valvano MR; Latiano T; Annese V; Andriulli A; di Sebastiano P
J Crohns Colitis; 2012 Jun; 6(5):563-70. PubMed ID: 22398048
[TBL] [Abstract][Full Text] [Related]
2. Serum prohepcidin levels in chronic inflammatory bowel diseases.
Nagy J; Lakner L; Poór VS; Pandur E; Mózsik G; Miseta A; Sipos K
J Crohns Colitis; 2010 Dec; 4(6):649-53. PubMed ID: 21122575
[TBL] [Abstract][Full Text] [Related]
3. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
Husain N; Tokoro K; Popov JM; Naides SJ; Kwasny MJ; Buchman AL
J Clin Gastroenterol; 2013 Mar; 47(3):246-51. PubMed ID: 23269308
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of YKL-40 in patients with inflammatory bowel disease.
Koutroubakis IE; Petinaki E; Dimoulios P; Vardas E; Roussomoustakaki M; Maniatis AN; Kouroumalis EA
Int J Colorectal Dis; 2003 May; 18(3):254-9. PubMed ID: 12673492
[TBL] [Abstract][Full Text] [Related]
5. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
[TBL] [Abstract][Full Text] [Related]
6. Mean platelet volume: a useful marker of inflammatory bowel disease activity.
Kapsoritakis AN; Koukourakis MI; Sfiridaki A; Potamianos SP; Kosmadaki MG; Koutroubakis IE; Kouroumalis EA
Am J Gastroenterol; 2001 Mar; 96(3):776-81. PubMed ID: 11280550
[TBL] [Abstract][Full Text] [Related]
7. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.
Miranda-García P; Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016 Oct; 39(8):508-15. PubMed ID: 27020243
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases.
Tavano F; Palmieri O; di Mola FF; Latiano A; Burbaci FP; Valvano MR; Corritore G; Augello B; Merla G; Annese V; Andriulli A; di Sebastiano P
Dig Liver Dis; 2013 Dec; 45(12):1003-10. PubMed ID: 23827863
[TBL] [Abstract][Full Text] [Related]
9. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease.
Bross DA; Leichtner AM; Zurakowski D; Law T; Bousvaros A
J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):164-71. PubMed ID: 8856584
[TBL] [Abstract][Full Text] [Related]
10. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
11. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum eotaxin levels in patients with inflammatory bowel disease.
Mir A; Minguez M; Tatay J; Pascual I; Peña A; Sanchiz V; Almela P; Mora F; Benages A
Am J Gastroenterol; 2002 Jun; 97(6):1452-7. PubMed ID: 12094864
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic problems and advances in inflammatory bowel disease.
Odze R
Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
[TBL] [Abstract][Full Text] [Related]
15. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease.
Hyams JS; Fitzgerald JE; Treem WR; Wyzga N; Kreutzer DL
Gastroenterology; 1993 May; 104(5):1285-92. PubMed ID: 7683293
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
Naftali T; Novick D; Gabay G; Rubinstein M; Novis B
Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
[TBL] [Abstract][Full Text] [Related]
17. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].
Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF
Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976
[TBL] [Abstract][Full Text] [Related]
18. Measles IgM immunoreactivity in patients with inflammatory bowel disease.
Balzola FA; Khan K; Pera A; Bonino F; Pounder RE; Wakefield AJ
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):378-82. PubMed ID: 9789132
[TBL] [Abstract][Full Text] [Related]
19. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease.
Ojuawo A; Keith L
Cent Afr J Med; 2002; 48(9-10):116-9. PubMed ID: 14562534
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
